Phys.OrgFirst CRISPR single-nucleotide edited transgenic micePhys.OrgThe most recent and highly successful CRISPR-Cas9 technique works by cutting around the faulty nucleotide in both strands of the DNA and cuts out a small part of DNA. Conversely, IBS … Continue reading
OncLive |
New antiviral drug cuts cytomegalovirus infection, improves survival in patients undergoing donor stem cell transplant
Science Daily In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has shown that a novel agent can protect against the most … Dr. Marty on Letermovir for CMV Prevention After Stem Cell TransplantOncLive Letermovir Prevents CMV Infection Post-HSCT in Phase 3 StudyMonthly Prescribing Reference (registration) Positive Phase III Data for Merck Candidates against CMV and ShinglesGenetic Engineering & Biotechnology News (blog) |
Medical News Today |
Cancer: New way of tracking rare T cells should improve immunotherapy
Medical News Today Immunotherapy is an exciting new field in the fight against cancer that uses cells from the patient’s own immune system to tackle the disease. However, as in all new medical approaches, it faces immense challenges. From a theoretical standpoint, the … |
Xconomy |
Advaxis Licenses Antigen Delivery Technology to Sellas for Cancer Immunotherapy
Genetic Engineering & Biotechnology News (press release) Advaxis has licensed its proprietary Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358 million for Advaxis, the companies said today. Sellas plans to develop a cancer immunotherapy … Advaxis Inks Deal with Sellas to Develop New Cancer ImmunotherapyXconomy Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting ImmunotherapyEconoTimes Advaxis pens backloaded $358M cancer delivery tech dealFierceBiotech |